BG64540B1 - Използване на дексмедетомидин за постигане на седативен ефект в отделение за интензивна терапия - Google Patents

Използване на дексмедетомидин за постигане на седативен ефект в отделение за интензивна терапия Download PDF

Info

Publication number: BG64540B1
Authority: BG; Bulgaria
Prior art keywords: dexmedetomidine; patient; patients; dose; sedation
Prior art date: 1998-04-01

Application number

BG104797A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG104797A (en

Inventor

Riku Aantaa

Romeo Bachand

Esa Heinonen

Original Assignee

Orion Corporation

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-01

Filing date

2000-09-26

Publication date

2005-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26763325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64540(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-09-26 Application filed by Orion Corporation, Abbott Laboratories filed Critical Orion Corporation

2001-07-31 Publication of BG104797A publication Critical patent/BG104797A/xx

2005-07-29 Publication of BG64540B1 publication Critical patent/BG64540B1/bg

Links

HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 title claims abstract description 155
229960004253 dexmedetomidine Drugs 0.000 title claims abstract description 155
230000001624 sedative effect Effects 0.000 title claims abstract description 31
150000003839 salts Chemical class 0.000 claims abstract description 30
239000013543 active substance Substances 0.000 claims abstract description 12
206010039897 Sedation Diseases 0.000 claims description 68
230000036280 sedation Effects 0.000 claims description 68
238000012423 maintenance Methods 0.000 claims description 29
239000003814 drug Substances 0.000 claims description 24
230000036470 plasma concentration Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 4
230000000699 topical effect Effects 0.000 claims 2
238000000034 method Methods 0.000 abstract description 13
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 56
238000001802 infusion Methods 0.000 description 53
229960005181 morphine Drugs 0.000 description 28
239000000932 sedative agent Substances 0.000 description 27
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 25
229960003793 midazolam Drugs 0.000 description 25
229960004134 propofol Drugs 0.000 description 22
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 22
229940079593 drug Drugs 0.000 description 21
230000000694 effects Effects 0.000 description 21
238000001356 surgical procedure Methods 0.000 description 21
208000002193 Pain Diseases 0.000 description 20
230000036407 pain Effects 0.000 description 20
238000002474 experimental method Methods 0.000 description 17
239000000902 placebo Substances 0.000 description 14
229940068196 placebo Drugs 0.000 description 14
229940125723 sedative agent Drugs 0.000 description 14
230000002980 postoperative effect Effects 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
238000002627 tracheal intubation Methods 0.000 description 10
206010020772 Hypertension Diseases 0.000 description 9
208000004756 Respiratory Insufficiency Diseases 0.000 description 9
239000000556 agonist Substances 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
208000019901 Anxiety disease Diseases 0.000 description 8
208000028399 Critical Illness Diseases 0.000 description 8
206010038678 Respiratory depression Diseases 0.000 description 8
230000036592 analgesia Effects 0.000 description 8
230000036506 anxiety Effects 0.000 description 8
229940049706 benzodiazepine Drugs 0.000 description 8
150000001557 benzodiazepines Chemical class 0.000 description 8
229960002896 clonidine Drugs 0.000 description 8
229940127240 opiate Drugs 0.000 description 8
229940035676 analgesics Drugs 0.000 description 7
239000000730 antalgic agent Substances 0.000 description 7
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
230000000004 hemodynamic effect Effects 0.000 description 6
ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 5
230000002411 adverse Effects 0.000 description 5
230000036772 blood pressure Effects 0.000 description 5
229960003394 remifentanil Drugs 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
208000001953 Hypotension Diseases 0.000 description 4
230000000202 analgesic effect Effects 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
239000003193 general anesthetic agent Substances 0.000 description 4
230000036543 hypotension Effects 0.000 description 4
238000005399 mechanical ventilation Methods 0.000 description 4
238000002483 medication Methods 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
230000029058 respiratory gaseous exchange Effects 0.000 description 4
208000007848 Alcoholism Diseases 0.000 description 3
208000000044 Amnesia Diseases 0.000 description 3
208000031091 Amnestic disease Diseases 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
206010002383 Angina Pectoris Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
230000006986 amnesia Effects 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
229940035674 anesthetics Drugs 0.000 description 3
239000002220 antihypertensive agent Substances 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
230000000949 anxiolytic effect Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000036471 bradycardia Effects 0.000 description 3
208000006218 bradycardia Diseases 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
208000019622 heart disease Diseases 0.000 description 3
150000003840 hydrochlorides Chemical class 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000009423 ventilation Methods 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000020446 Cardiac disease Diseases 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010034246 Pelvic fractures Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010041349 Somnolence Diseases 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
229940005530 anxiolytics Drugs 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229940125717 barbiturate Drugs 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
201000010099 disease Diseases 0.000 description 2
230000005176 gastrointestinal motility Effects 0.000 description 2
238000002695 general anesthesia Methods 0.000 description 2
208000011316 hemodynamic instability Diseases 0.000 description 2
-1 hydrochloric Chemical class 0.000 description 2
208000008384 ileus Diseases 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
230000015654 memory Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
238000013059 nephrectomy Methods 0.000 description 2
239000000842 neuromuscular blocking agent Substances 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000000554 physical therapy Methods 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
230000000250 revascularization Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000004448 titration Methods 0.000 description 2
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010071238 Binge Drinking Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
206010019708 Hepatic steatosis Diseases 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010029148 Nephrolithiasis Diseases 0.000 description 1
241000009328 Perro Species 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
239000000219 Sympatholytic Substances 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
208000007474 aortic aneurysm Diseases 0.000 description 1
206010002906 aortic stenosis Diseases 0.000 description 1
210000001765 aortic valve Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
230000001914 calming effect Effects 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000002600 fibrillogenic effect Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000297 inotrophic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
CUHVIMMYOGQXCV-LLVKDONJSA-N levomedetomidine Chemical compound C1([C@H](C)C=2C(=C(C)C=CC=2)C)=CNC=N1 CUHVIMMYOGQXCV-LLVKDONJSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
229960002140 medetomidine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012806 monitoring device Methods 0.000 description 1
229960004715 morphine sulfate Drugs 0.000 description 1
GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
229960005457 pancuronium Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
208000023974 pharynx neoplasm Diseases 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000005801 respiratory difficulty Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
230000026416 response to pain Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960004739 sufentanil Drugs 0.000 description 1
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000000948 sympatholitic effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000035922 thirst Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG104797A 1998-04-01 2000-09-26 Използване на дексмедетомидин за постигане на седативен ефект в отделение за интензивна терапия BG64540B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8028798P	1998-04-01	1998-04-01
US11094498P	1998-12-04	1998-12-04

Publications (2)

Publication Number	Publication Date
BG104797A BG104797A (en)	2001-07-31
BG64540B1 true BG64540B1 (bg)	2005-07-29

Family

ID=26763325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104797A BG64540B1 (bg)	1998-04-01	2000-09-26	Използване на дексмедетомидин за постигане на седативен ефект в отделение за интензивна терапия

Country Status (27)

Country	Link
EP (1)	EP1069893B1 (de)
JP (1)	JP4606581B2 (de)
KR (1)	KR20010034728A (de)
CN (1)	CN1168441C (de)
AR (1)	AR015744A1 (de)
AT (1)	ATE347359T1 (de)
AU (1)	AU754484B2 (de)
BG (1)	BG64540B1 (de)
BR (1)	BR9909872A (de)
CA (1)	CA2326339C (de)
CZ (1)	CZ301013B6 (de)
DE (1)	DE69934305T2 (de)
DK (1)	DK1069893T3 (de)
EA (1)	EA005524B1 (de)
ES (1)	ES2278441T3 (de)
GB (1)	GB2352972B (de)
HU (1)	HU229162B1 (de)
IL (1)	IL138416A (de)
NO (1)	NO329194B1 (de)
NZ (1)	NZ507203A (de)
PL (1)	PL192517B1 (de)
PT (1)	PT1069893E (de)
SI (1)	SI1069893T1 (de)
SK (1)	SK286160B6 (de)
TR (1)	TR200002837T2 (de)
TW (1)	TW552136B (de)
WO (1)	WO1999049854A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60024855T2 (de)	1999-10-29	2006-08-31	Orion Corp.	Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock
CA2480881C (en) *	2002-04-08	2012-09-11	Guilford Pharmaceuticals, Inc.	Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
US7141597B2 (en) *	2003-09-12	2006-11-28	Allergan, Inc.	Nonsedating α-2 agonists
US20060058700A1 (en) *	2004-08-26	2006-03-16	Marro Dominic P	Patient sedation monitor
ES2573253T3 (es)	2006-09-20	2016-06-06	The Board Of Regents Of The University Of Texas System	Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor
EP3581169A1 (de)	2008-01-22	2019-12-18	The Board Of Regents Of The University Of Texas System	Flüchtige anästhesiemittelzusammensetzungen mit extraktiven lösungsmitteln für lokale anästhesie und/oder schmerzlinderung
RU2572692C2 (ru) *	2009-05-15	2016-01-20	Рекро Фарма, Инк.	Сублингвальные композиции дексмедетомидина и способы их применения
DE102009050016A1 (de)	2009-05-27	2011-05-05	Modine Manufacturing Co., Racine	Wärmeübertragereinheit
US20130096170A1 (en) *	2011-10-14	2013-04-18	Hospira, Inc.	Methods of treating pediatric patients using dexmedetomidine
AU2012352528B9 (en)	2011-12-11	2017-11-02	Baudax Bio, Inc.	Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) *	2012-01-04	2012-08-14	Hospira, Inc.	Dexmedetomidine premix formulation
JP5921928B2 (ja) *	2012-03-28	2016-05-24	テルモ株式会社	既希釈デクスメデトミジン製剤
DK2906213T3 (en) *	2012-10-15	2018-02-19	Orion Corp	VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY
WO2015011177A1 (en)	2013-07-24	2015-01-29	I-Tech Ab	Use of the enantiomer levomedetomidine as inhibitor for marine biofouling of surfaces
BR112016006848A2 (pt)	2013-10-07	2017-08-01	Teikoku Pharma Usa Inc	métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
KR101827980B1 (ko)	2013-10-07	2018-02-13	테이코쿠 팔마 유에스에이, 인코포레이티드	덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CA2924233C (en) *	2013-10-07	2018-10-23	Teikoku Pharma Usa, Inc.	Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
TWI764951B (zh)	2016-10-31	2022-05-21	美商帝國製藥美國股份有限公司	用於處理疼痛之右美托咪啶經皮遞送裝置
CN113975273B (zh) *	2020-07-27	2023-07-11	宜昌人福药业有限责任公司	一种抗焦虑用纳米混悬鼻腔喷雾剂及其制备方法
CN115197149B (zh) *	2021-04-02	2023-09-22	四川大学华西医院	一种5-苄基咪唑类化合物及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4544664A (en) *	1981-07-10	1985-10-01	Farmos Group, Ltd.	Antihypertensive substituted imidazole derivatives
US4670455A (en) *	1984-12-04	1987-06-02	Farmos-Yhtyma Oy	Method of bringing about sedation and/or analgesia in a mammal
US4910214A (en) *	1987-07-16	1990-03-20	Farmos Yhtyma Oy	Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist
US5344840A (en) *	1988-02-29	1994-09-06	Orion-Yhtyma Oy	4-substituted imidazole derivatives useful in perioperative care
US5712301A (en) *	1993-08-25	1998-01-27	Orion-yhtyma Oy	Use of dexmedetomidine for treating ethanol-induced neurodegeneration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2215206B (en) *	1988-02-29	1991-07-03	Farmos Oy	4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) *	1989-08-18	1992-06-23	Cygnus Therapeutic Systems	Method and device for administering dexmedetomidine transdermally
US5217718A (en) *	1989-08-18	1993-06-08	Cygnus Therapeutic Systems	Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) *	1989-10-17	1989-10-17	Farmos Oy	En terapeutiskt vaerdefull foerening.

1999
- 1999-03-30 AR ARP990101414A patent/AR015744A1/es unknown
- 1999-03-31 GB GB0024932A patent/GB2352972B/en not_active Expired - Lifetime
- 1999-03-31 BR BRPI9909872-5A patent/BR9909872A/pt not_active Application Discontinuation
- 1999-03-31 SK SK1436-2000A patent/SK286160B6/sk not_active IP Right Cessation
- 1999-03-31 ES ES99913332T patent/ES2278441T3/es not_active Expired - Lifetime
- 1999-03-31 CA CA002326339A patent/CA2326339C/en not_active Expired - Lifetime
- 1999-03-31 PT PT99913332T patent/PT1069893E/pt unknown
- 1999-03-31 TR TR2000/02837T patent/TR200002837T2/xx unknown
- 1999-03-31 DE DE69934305T patent/DE69934305T2/de not_active Expired - Lifetime
- 1999-03-31 HU HU0101498A patent/HU229162B1/hu unknown
- 1999-03-31 AU AU31494/99A patent/AU754484B2/en not_active Expired
- 1999-03-31 KR KR1020007010991A patent/KR20010034728A/ko not_active Ceased
- 1999-03-31 EP EP99913332A patent/EP1069893B1/de not_active Expired - Lifetime
- 1999-03-31 CZ CZ20003484A patent/CZ301013B6/cs not_active IP Right Cessation
- 1999-03-31 NZ NZ507203A patent/NZ507203A/xx not_active IP Right Cessation
- 1999-03-31 WO PCT/FI1999/000266 patent/WO1999049854A2/en not_active Ceased
- 1999-03-31 SI SI9930941T patent/SI1069893T1/sl unknown
- 1999-03-31 IL IL13841699A patent/IL138416A/xx not_active IP Right Cessation
- 1999-03-31 PL PL343553A patent/PL192517B1/pl unknown
- 1999-03-31 DK DK99913332T patent/DK1069893T3/da active
- 1999-03-31 JP JP2000540820A patent/JP4606581B2/ja not_active Expired - Lifetime
- 1999-03-31 EA EA200001010A patent/EA005524B1/ru not_active IP Right Cessation
- 1999-03-31 AT AT99913332T patent/ATE347359T1/de active
- 1999-03-31 CN CNB998046272A patent/CN1168441C/zh not_active Ceased
- 1999-04-01 TW TW088105188A patent/TW552136B/zh not_active IP Right Cessation
2000
- 2000-09-26 BG BG104797A patent/BG64540B1/bg unknown
- 2000-09-29 NO NO20004931A patent/NO329194B1/no not_active IP Right Cessation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4544664A (en) *	1981-07-10	1985-10-01	Farmos Group, Ltd.	Antihypertensive substituted imidazole derivatives
US4670455A (en) *	1984-12-04	1987-06-02	Farmos-Yhtyma Oy	Method of bringing about sedation and/or analgesia in a mammal
US4910214A (en) *	1987-07-16	1990-03-20	Farmos Yhtyma Oy	Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist
US5344840A (en) *	1988-02-29	1994-09-06	Orion-Yhtyma Oy	4-substituted imidazole derivatives useful in perioperative care
US5712301A (en) *	1993-08-25	1998-01-27	Orion-yhtyma Oy	Use of dexmedetomidine for treating ethanol-induced neurodegeneration

Also Published As

Publication number	Publication date
BG104797A (en)	2001-07-31
GB2352972A (en)	2001-02-14
PT1069893E (pt)	2007-01-31
EA200001010A1 (ru)	2001-02-26
EA005524B1 (ru)	2005-04-28
CZ301013B6 (cs)	2009-10-14
EP1069893A2 (de)	2001-01-24
GB2352972B (en)	2003-05-21
JP4606581B2 (ja)	2011-01-05
ATE347359T1 (de)	2006-12-15
PL192517B1 (pl)	2006-10-31
ES2278441T3 (es)	2007-08-01
AU754484B2 (en)	2002-11-14
KR20010034728A (ko)	2001-04-25
NO20004931D0 (no)	2000-09-29
DE69934305D1 (de)	2007-01-18
TW552136B (en)	2003-09-11
WO1999049854A2 (en)	1999-10-07
EP1069893B1 (de)	2006-12-06
IL138416A (en)	2005-07-25
SK14362000A3 (sk)	2002-03-05
HUP0101498A3 (en)	2002-06-28
CA2326339A1 (en)	1999-10-07
HUP0101498A1 (hu)	2002-03-28
TR200002837T2 (tr)	2001-01-22
GB0024932D0 (en)	2000-11-29
CA2326339C (en)	2008-12-23
CN1295473A (zh)	2001-05-16
CN1168441C (zh)	2004-09-29
AU3149499A (en)	1999-10-18
DK1069893T3 (da)	2007-03-19
DE69934305T2 (de)	2007-07-12
WO1999049854A3 (en)	1999-11-18
AR015744A1 (es)	2001-05-16
HU229162B1 (hu)	2013-09-30
JP2002509880A (ja)	2002-04-02
CZ20003484A3 (cs)	2002-01-16
SI1069893T1 (sl)	2007-04-30
NO20004931L (no)	2000-09-29
PL343553A1 (en)	2001-08-27
BR9909872A (pt)	2007-11-20
IL138416A0 (en)	2001-10-31
NO329194B1 (no)	2010-09-13
SK286160B6 (sk)	2008-04-07
NZ507203A (en)	2003-03-28

Publication	Publication Date	Title
BG64540B1 (bg)	2005-07-29	Използване на дексмедетомидин за постигане на седативен ефект в отделение за интензивна терапия
Darrouj et al.	2008	Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal
US6716867B1 (en)	2004-04-06	Use of dexmedetomidine for ICU sedation
Cromhout	2003	Ketamine: its use in the emergency department
JP2013541583A (ja)	2013-11-14	組み合わせ組成物
Hassan	2015	Dexmedetomidine versus ketofol for moderate sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) comparative study
US20130123298A1 (en)	2013-05-16	Pharmaceutical composition for the prevention of perioperative arterial hypotension in humans
Hellyer	2020	Pain management
Ali et al.	2016	Dexmedetomidine versus ketofol effect on the incidence of emergence agitation associated with sevoflurane-based anesthesia in children undergoing orthopedic surgery
Imbelloni et al.	2019	Low dose of isobaric bupivacaine provides lower incidence of spinal hypotension for hip surgery in elderly patients
Walder et al.	2002	Propofol and midazolam versus propofol alone for sedation following coronary artery bypass grafting: a randomized, placebo-controlled trial
AU2023257182A1 (en)	2024-12-05	Aqueous quetiapine solutions
RU2557882C1 (ru)	2015-07-27	Способ проведения премедикации при плановом хирургическом лечении
Mamatha	2019	Comparative study between dexmedetomidine and midazolam in inducing conscious sedation in patient undergoing cataract surgery
RU2664693C1 (ru)	2018-08-21	Способ предоперационной подготовки пациентов к офтальмологическим операциям
Ramya	2018	A Comparative Study Of Dexmedetomidine Versus Midazolam For Monitored Anaesthesia Care In Middle Ear Surgeries
FRH	2019	Comparison of Intrathecal Dexmedetomidine and Buprenorphine as Adjuvant to Bupivacaine for Lower Limb Surgeries
Hiremath	2016	A Clinical Comparative Study of Propofol and Ketamine Combination (Ketofol) Versus Either Drug Alone in Short Surgeries and Procedures
Joffe et al.	2009	Transient anesthetic-induced worsening of existing left-sided weakness in a patient undergoing elective anterior cervical discectomy
Bergfeld et al.	2001	Sedation and Analgesia
MSNA	2017	Sickle Cell Disease and Ketamine Use in Endoscopy
Watcha et al.	0	Paul F. White PhO Mo FFARCAS, M. Barry Jones MD, Richard G. Lagueruela MD, Raghu P. Terkonda tad
JPH10287568A (ja)	1998-10-27	アルコール依存症治療剤
Shah	0	Comparative Study Between Transdermal Buprenorphine Patch and Fentanyl Patch in Enhancing the Post-Operative Analgesic Effect of Intrathecal Clonidine in Lower Limb Surgery
WO2005074928A1 (ja)	2005-08-18	高血圧症治療薬